As per usual, a bill that has no purpose other than shifting costs from patients to taxpayers at large, while keeping profit of pharma and insurance companies untouched and untamed price hiking
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology